

OTM: FY09 Year to Date and FY08 End of Year Results

	FY 2008 Total			FY 2009 Year to Date		
	Chicago	Urbana	Total	Chicago	Urbana	Total
Disclosures Received	120	244	364	28	69	97
U. S. Patents Filed	184	181	365	45	41	86
U. S. Patents Issued	16	38	54	4	5	
Licenses & Options	18	43	61	2	8	10
Licenses to Start-Ups	. 5	6	11	0	1	1
*Royalties Earned	\$4.477M	\$4.235M	\$8.712M	\$2.178M	\$1.232M	\$3.41M
Patent Cost Reimbursement	\$0.266M	\$0.899M	\$1.165M	\$0.049M	\$0.393M	\$0.442M
Non-University Share	\$0.577M	\$0.178M	\$0.755M	\$0.001M	\$0.000M	\$0.001M
**Net for Distribution	\$3.637M	\$2.816M	\$6.453M	\$1.9 2 2M	\$0.855M	\$2.777 Ⅳ

*In FY08 \$1,481,855 was distributed to inventors, and \$2,635,673 was returned to the campuses and campus units.

**FY09 year to date, \$825,329 was distributed to inventors, and \$1,747,849 was returned to the campuses and campus units.

computational efficiency of image reconstruction in CT, PET, SPECT, and MRI.

iSense Corporation is dedicated to the development and manufacture of a minimally-invasive continuous glucose monitor. iSense has built a portfolio of intellectual property through a combination of licensing agreements, partnerships and selffunded research.

Pattern Insight provides information technology professionals with scalable solutions to intelligently analyze, search, and mine valuable information contained in technical data. Their solutions help to reduce the cost of operations and technology development and mitigate risk.

the human eye.

detector pixels.

LK4 LK4 Technology Corporation licensed the University's web accessibility wizard, a technology that provides a simple way to create web versions of Office documents that are more accessible and usable by everyone, including people with disabilities.

TED*update* **Report to the Technology and Economic Development Committee**

this issue

Stretchable Silicon, Licensed Startups P.1

Prezista[™], OTM Director Named, LES Award P.2

Eden Park Illumination. IllinoisVENTURES P.3

Offices of Technology Management,

Research Park at the University of Illinois P.4

Heart, Brain and Eyes -- for bendable and stretchable silicon, the possibilities are endless...

a technology that can be used to create devices such as a bendable pacemaker or a sensor for the brain that can detect seizures before they begin. The first step toward human application is an artificial retina that works like a lens on a camera.

As reported in cover stories in both the September 22 edition of *EE Times* and the August 7 issue of *Nature*, Rogers based the design of the camera on a human eye - which has a simple, single-element lens and a hemispherical detector. The camera integrates such a detector with a hemispherical cap and imaging lens to yield a system with the overall size, shape and layout of

Rogers and his team made the camera by first molding a thin rubber membrane in the shape of a hemisphere. The rubber membrane is then stretched with a specialized mechanical stage to form a flat drumhead. Next, a prefabricated focal plan array and associated electronics are transferred from a silicon wafer to the tensioned. drumhead membrane. When the tension is released, the membrane returns to its original shape. This process compresses the focal plane array, causing specially designed electrical interconnects to delaminate from the rubber surface and form arcs, pinned on the ends by

These deformations accommodate strains associated with the planar to hemispherical transformation, without stressing the silicon, as confirmed by mechanics modeling performed by researchers at Northwestern. The array package is then transferred to a matching hemispherical glass substrate. A lens and a camera connected to external electronics finalizes the process. Though low resolution, the electronic eye still produced a recognizable picture.

This technology has been optioned by the startup company, MC10 Inc., an electronic materials company that combines several proprietary technologies to make responsive devices and products. The technical approach underlying these devices have been designed and engineered by several top academic thought leaders in material science and chemistry. The business model of the company is to broadly advance its core technologies to address product opportunities in a variety of industries. MC10 is a combination platform-product company.



OTM Licensed Start-Ups

Continued from Page 1

NanoSi Advanced Technologies The company's silicon nanoparticles have several pivotal characteristics that may enable solar application.

GeeYee Inc. empowers companies and organizations to learn, discover and benefit from the opinions and experiences of others regarding brands, products and services by applying its patent-pending, featurebased sentiment analysis technology to extract, summarize and quantify unstructured opinions from User Generated Content (UGC) found in review sites, forums and blogs on any subject matter at the feature and attribute level.

Steady Sleep Rx Co. ("SSRx") The strategy of SRRx is to build a pipeline of products, all aimed at treating the cause of sleep apnea, an irregular central neural output patterning to the respiratory system. Traditionally this condition has been treated with medical devices that are uncomfortable and have a very low compliance rate. Sleep apnea affects 15 to 18 million people in the US and is a billion dollar market in the US and \$1.5 billion globally.

WebScalers provides solutions to various business problems associated with online search coverage, quality, and effectiveness. The technology is based upon collaborative research and development between universities and the company and is funded by the National Science Foundation and can deliver in timesensitive and location-specific information from surface and deep Web. The technology platform can be used to build various industryspecific vertical applications.

Intelligent Instrument Magneto-elastic stress sensor company.

Sanogene Therapeutics Inc. utilizes breakthrough ribonucleic acid interference (RNAi) technology to develop biopharmaceutical products for incurable cancers.

Prezista™ Leads the Next Generation of HIV Drugs

HIV mutates quickly, which can rapidly render drugs ineffectual. The FDA granted accelerated approval for the anti-HIV medicine, Prezista™, in June 2006 and has indicated its use in salvage therapy, a form of treatment given after an ailment does not respond to standard treatment. For the thousands of patients with multiresistant strains of the HIV virus, Prezista[™] is proving a potent option in their fight against the disease.

Possessed of a novel molecular structure, Prezista™ is always co-administered with ritonavir, a protease inhibitor which slows the breakdown of the drug in the body, and other antiretroviral agents.

They work together to minimize the risk of a patient developing resistance to the drugs. Prezista is one of two second-generation protease inhibitors providing a major advance in drug resistance.





They work together to minimize the risk of a patient developing resistance to the drugs. Prezista is one of two second-generation protease inhibitors providing a major advance in drug resistance.

Prezista[™] was developed at the University of Illinois by Dr. Arun Ghosh of the Department of Chemistry (now at Purdue University) with support and collaboration from the National Institutes of Health. In 1999. Prezista[™] was licensed to Tibotec Therapeutics, a division of Ortho Biotech Products, L.P.



Nancy Sullivan Named Technology Management Director at Chicago

Nancy Sullivan has been named director of the Office of Technology Management located at the Chicago campus subject to Board of Trustees approval.

Sullivan was the senior director of business development for KeraCure, an early-stage biotechnology company currently in clinical trials of a cell-based device for treatment of chronic wounds. Previously, Sullivan was director of the Women's Entrepreneurial Life Sciences Initiative at Northwestern University.

Sullivan said she was eager to begin her new position November 3.

"UIC has a strong research foundation in many important areas. Life sciences research has the potential to provide life saving cures for deadly diseases as well as to create new biotechnology-based businesses," she said.

"In addition, the OTM will increase licensing revenues to UIC, offer services to assist faculty and staff to commercialize their research and serve as a tangible benefit in the recruitment of top research professors," she said.

Sullivan earned her MBA and M.S. in biotechnology from Northwestern and her bachelor's degree in business administration from Loyola University.

LES Deals of Distinction Award™

The University of Illinois shared the honor of the Licensing Executives Society **Deals of Distinction Award**TM presented at the LES Annual meeting in October.

The Industry/University and Government Laboratory Interactions (IUGI) Sector winner was a partnership led by UC-Berkeley in collaboration with Lawrence Berkeley Laboratory and the University of Illinois, that was selected as the recipient of a \$500M, 10-year grant from the Energy Biosciences Institute.

The partnership is unique in scope and the deal enables the partners to leverage complimentary skills, expertise and resources in a way that has the potential to result in the development of novel energy sources and solutions that could significantly benefit the global community.

EDEN PARK

Eden Park Illumination Develops Brightest Flat Light

Eden Park Illumination, Inc. was founded in May 2007, by Professors J. Gary Eden and Sung-Jin Park and IllinoisVENTURES. The company is an innovator in the research, development and commercialization of Microcavity Plasma (or "Microplasma") lighting technology.

This platform technology provides a new and proprietary, ultrathin light source which offers unique advantages over both traditional light sources (incandescent and fluorescent) and the newer lighting technologies - light emitting diodes ("LED") and organic light emitting diodes ("OLED").

This lighting technology is distinctive from existing light sources and Eden Park Illumination will open up new opportunities for general illumination as well as architectural lighting. In addition to producing light levels suitable for illumination applications and being very energy efficient, Microplasma is a clean energy, mercury-free light source with a long expected lifetime.



IllinoisVENTURES, LLC

Total funding to date now approximately \$25.7 M with of third-party investor and grant funding.

Summary	Total nce January	
Clients:	Engaged Consultatively	994
	Receiving Developmental Funding	61
*Funding:	Dollars Approved	\$25,700,000
	Dollars Funded*	\$24,950,000
Additional 3 ^{rc}	\$246,000,000*	
*Excludes \$110M	raise by Phoenix Coal	

h over 10:1 "leverage"



Eden Park Illumination's progress has accelerated considerably over the last several months and the company has achieved several milestones:

January 2008 - moved R&D operations to Enterprise Works and began prototype development.

April 2008 - hired Philip G. Warner as President and CEO. Prior to joining Eden Park Illumination Mr. Warner held a number of senior national and international management positions with Philips Lighting in the United Kingdom, the Netherlands (Philips Global HQ), and North America.

May 2008 - Clara Powell joined the company as the Vice President of Marketing and Business Development.

July 2008 - Eden Park Illumination celebrated the grand opening of its new Corporate and Marketing Operations in Somerset, NJ.

September 2008 - Major breakthrough as Eden Park demonstrates an early prototype of an ultra-thin flat light tile giving the light output equivalent to fluorescent lighting.